Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
- PMID: 10348825
- DOI: 10.1016/s0016-5085(99)70506-8
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
Abstract
Background & aims: The spectrum of nonalcoholic fatty liver disease ranges from fatty liver alone to nonalcoholic steatohepatitis. Most previous studies have short follow-up and have not carefully delineated different histological types when determining clinical outcomes. The aim of this study was to compare clinical characteristics and outcomes of patients with different types of nonalcoholic fatty liver.
Methods: All liver biopsy specimens from 1979 to 1987 with fat accumulation were assessed for inflammation, ballooning degeneration, Mallory hyaline, and fibrosis. Biopsy specimens were also assessed for histological iron and hepatitis C RNA. Outcomes were cirrhosis, mortality, and liver-related mortality.
Results: Of 772 liver biopsy specimens, complete data were available in 132 patients. Fatty liver (type 1) did not differ from the other three types combined with respect to gender, race, age, or obesity. Cirrhosis was more common in the other types combined (22%) than fatty liver alone (4%; P </= 0.001). Overall mortality, histological iron, and hepatitis C did not differ between groups. Most of the liver-related deaths were in type 4.
Conclusions: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver. These poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Similar articles
-
Nonalcoholic fatty liver disease: a systematic review.JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. JAMA. 2015. PMID: 26057287 Review.
-
[Nonalcoholic steatohepatitis: a brief review on its concept].Nihon Rinsho. 2006 Jun;64(6):1021-4. Nihon Rinsho. 2006. PMID: 16768104 Review. Japanese.
-
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.Hum Pathol. 2004 Feb;35(2):196-9. doi: 10.1016/j.humpath.2003.09.018. Hum Pathol. 2004. PMID: 14991537
-
Hepatic iron and nonalcoholic fatty liver disease.Hepatology. 1999 Oct;30(4):847-50. doi: 10.1002/hep.510300407. Hepatology. 1999. PMID: 10498632
-
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.Hepatology. 1990 Jan;11(1):74-80. doi: 10.1002/hep.1840110114. Hepatology. 1990. PMID: 2295475
Cited by
-
Envisioning how to advance the MASH field.Nat Rev Gastroenterol Hepatol. 2024 Jun 4. doi: 10.1038/s41575-024-00938-9. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38834817 Review.
-
Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease.World J Hepatol. 2024 May 27;16(5):688-702. doi: 10.4254/wjh.v16.i5.688. World J Hepatol. 2024. PMID: 38818294 Free PMC article. Review.
-
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.Curr Obes Rep. 2024 May 29. doi: 10.1007/s13679-024-00574-z. Online ahead of print. Curr Obes Rep. 2024. PMID: 38809396 Review.
-
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.Hepatol Commun. 2024 May 10;8(6):e0423. doi: 10.1097/HC9.0000000000000423. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727678 Free PMC article.
-
L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism.Cells. 2024 Apr 23;13(9):732. doi: 10.3390/cells13090732. Cells. 2024. PMID: 38727268 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical